Loss of function of FBXW7 in several human cancers has clinical implications and prognostic value: the use of rapamycin has proven to inhibit breast cancer cells with loss of FBXW7 by mTOR inhibition (Mao et al., 2008; Yeh et al., 2018). Here, MTOR is linked to cancer.